INmune Bio Inc.

US$1.13As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:INMBHealthcare
Country USA
PE (Fwd) •••
TSR 8Y CAGR (22.44%)
Div yield —
ROE (76.71%)
Biotechnology
Beta (5Y) 0.94
PE TTM —
TSR TTM (38.25%)
Mkt cap US$34.75M
ROIC (48.56%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.24
9.88%
(79.98%)
Hold 7|11|5|4|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
26.36%
16.80%
11.08%
9.56%
Revenue$M
2.395
2.343
2.463
2.555
(6.54%)
(5.94%)
(1.45%)
3.54%
Peers (US$34.75M)
Cap (US$)
PE
35.03M
61.89x
34.74M
—
Capital
TTM
5Y
10Y
Leveragex
0.226
0.128
0.111
EBIT/Intx
0.457
0.052
0.066
Own earn%
32.87
(42.57)
(58.43)
Sh yield%
26.26
47.03
45.97
Owners
Insiders/Inst%
13.84
30.15
Short interest%
1.69
SBC / revenue%
0.27
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
15–25
$1 testx
—
Incr. ROIC%
0